Wednesday, July 8, 2026

Patent intelligence · US

US 9554999

Lyophilization of synthetic liposomal pulmonary surfactant

granted A61KA61K31/20A61K31/661A61K31/683
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 4
Patent details — US 9554999
Jurisdiction
US
Status
granted
Grant date
Jan 31, 2017
Expiration
Jan 26, 2037
Claims
16
CPC classes
A61K, A61K31/20, A61K31/661, A61K31/683
View on Google Patents ↗

Quick answer

US 9554999 (Lyophilization of synthetic liposomal pulmonary surfactant) is held by Windtree Therapeutics, Inc.. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61K, A61K31/20, A61K31/661, A61K31/683, A61K31/685, A61K38/395

More from Windtree Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12343350

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Expires Jun 26, 2045

    granted
  2. US 11583540

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Expires Feb 16, 2043

    granted
  3. US 11197869

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Expires Dec 9, 2041

    granted

Frequently asked questions

What is US patent 9554999?

US 9554999 (Lyophilization of synthetic liposomal pulmonary surfactant) is held by Windtree Therapeutics, Inc.. Status: granted. Granted Jan 31, 2017. Expires Jan 26, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9554999?

Windtree Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.

When does US 9554999 expire?

Our index shows an expiration date of Jan 26, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.